Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully ...

MDA5 is a critical cytoplasmic RNA sensor capable of triggering type I interferon pathways. This study shows that the E3 ...

Scientists at Livzon Pharmaceutical Group Inc., Shanghai Institute of Organic Chemistry and the University of Michigan have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ...

Researchers at the National Institutes of Health (NIH) and their collaborators have identified a protein, known as RNF114, ...

Neurotransmitters are key for synaptic transmission at axon terminals, but their transport modalities remain debated. This ...

NIH-Led Studies Point to Potential Development of a Cataract Drug – Findings Suggests a Surgery-Free Treatment ...

The growing challenge in cancer therapy lies in overcoming tumor heterogeneity, drug resistance, and associated side effects.

Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key ...

Abstract: The proper control of mitosis depends on the ubiquitin-mediated degradation of the right mitotic regulator at the right time. This is effected by the Anaphase Promoting Complex/Cyclosome ...